Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sharon Kedar
AddedMar 31, 2024
UpdatedMay 31, 2026
Sharon Kedar

Sharon Kedar

Co-Founder, Northpond Ventures

CrunchbaseLinkedIn

Sharon Kedar's Career

Northpond Ventures
Northpond Ventures

Bethesda, MD, US

Co-Founder
Hawthorne Effect
Hawthorne Effect

Lafayette, CA, US

Board Member· Board
Artisan Bio
Artisan Bio

Aurora, CO, US

Board Member· Board
Emulate
Emulate

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sharon Kedar's Career

Northpond Ventures
Northpond Ventures
Investment FirmInvestment Firm552018Bethesda, MD, US
Co-Founder

Leadership at Northpond Ventures

Mike RubinMike RubinCo-Founder
Shaan GandhiShaan GandhiBoard Member

Similar to Northpond Ventures

North South VenturesNorth South VenturesSan Francisco, CA, USest. 2021North South VenturesSan Francisco, CA, US · est. 2021

North South Ventures: A cross-border VC fund, investing in early-stage med companies, with $4B+ funding and 40+ FDA approvals.

Investment Firm8
Northwood VenturesNorthwood VenturesSyosset, NY, USest. 1983Northwood VenturesSyosset, NY, US · est. 1983

Northwood Ventures LLC: A US-based private equity firm specializing in venture capital, buyouts, and consolidations.

Investment Firm5
Northwest Technology VenturesNorthwest Technology VenturesPortland, OR, USest. 2002Northwest Technology VenturesPortland, OR, US · est. 2002

Northwest Technology Ventures: A US-based venture capital firm specializing in seed and early-stage investments in healthcare and technology sectors.

Investment Firm5
North Coast VenturesNorth Coast VenturesCleveland, OH, USest. 2006North Coast VenturesCleveland, OH, US · est. 2006

North Coast Ventures: A technology-focused capital partner accelerating early-stage B2B, SaaS ventures.

Investment Firm200
Hawthorne Effect
Hawthorne Effect
Acquired$23.1M02015Lafayette, CA, US
Board Member· Board

Leadership at Hawthorne Effect

Richard FerrariRichard FerrariBoard Member
Jodi AkinJodi AkinBoard Member
Ilya KirnosIlya KirnosBoard Member

Similar to Hawthorne Effect

ClinOneClinOneNeedham, MA, USClinical Trialsest. 2016ClinOneNeedham, MA, US · est. 2016

ClinOne: Streamlining clinical trials with web and mobile solutions for improved patient experience.

Series A · $10.5M75
Endpoint ClinicalEndpoint ClinicalSan Francisco, CA, USClinical Trial Softwareest. 2009Endpoint ClinicalSan Francisco, CA, US · est. 2009

Study software provider, Endpoint, designs and tests interactive data access platforms via phones.

Seed · $1.7M606
SubjectWellSubjectWellAustin, TX, USPatient Recruitmentest. 2012SubjectWellAustin, TX, US · est. 2012

SubjectWell: A risk-free marketplace for efficient patient recruitment in clinical trials.

Series B · $46.8M185
Clinical.LyClinical.LyNew York City, NY, USClinical Research, Softwareest. 2019Clinical.LyNew York City, NY, US · est. 2019

Clinical.ly: Streamlining clinical research with intuitive, tailored tech solutions.

Pre-Seed · $1.1M30
Artisan Bio
Artisan Bio
Series A$21M452019Aurora, CO, US
Board Member· Board

Leadership at Artisan Bio

Ryan T. GillRyan T. GillCEO
Tanya WarneckeTanya WarneckeFounder
Emulate
Emulate
Series E$224.3M1192013Boston, MA, US
Board Member· Board

Leadership at Emulate

Jim CorbettJim CorbettBoard Member
Eric MoessingerEric MoessingerBoard Member
Daniel LevnerDaniel LevnerBoard Member
Donald IngberDonald IngberBoard Member
Aaron VanDevenderAaron VanDevenderBoard Member
Martin MadausMartin MadausBoard Member

Similar to Emulate

eGenesiseGenesisCambridge, MA, USGene Editing, Organsest. 2015eGenesisCambridge, MA, US · est. 2015

eGenesis: Revolutionizing transplantation with a gene editing platform for human-compatible organs.

Series C · $265M105
Systemic BioSystemic BioHouston, TX, USOrgans-On-Chipsest. 2022Systemic BioHouston, TX, US · est. 2022

Systemic Bio leverages 3D technology to create bioprinted organs-on-chips for advanced drug discovery.

Seed · $15M11
BiomedInnovationsBiomedInnovationsDenver, NC, USMedical Devicesest. 2015BiomedInnovationsDenver, NC, US · est. 2015

BiomedInnovations: Pioneering tech for long-term storage and interaction with human tissues/organs.

Angel · $250k12
VivoSim LabsVivoSim LabsSan Diego, CA, USBioprinting, Medical Researchest. 2011VivoSim LabsSan Diego, CA, US · est. 2011

Innovative San Diego-based company specializing in 3D bioprinting for medical research and therapy.

Public · $112.3M39

Sharon Kedar's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Sharon Kedar

Frank M. SandsFrank M. SandsChief Executive Officer · Sands CapitalJohn RyuJohn RyuCo-Founder · HypothesisNeil ParikhNeil ParikhCo-Founder · CasperNick RosaNick RosaCo-Founder · Sandbox Investment ManagementBill KurtzBill KurtzBoard Member · AterianSherwood (Woodie) NeissSherwood (Woodie) NeissBoard Member · SeedInvest